Literature DB >> 9174684

Effects of grapefruit juice ingestion--pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men.

J Lundahl1, C G Regårdh, B Edgar, G Johnsson.   

Abstract

OBJECTIVE: To examine the effect of grapefruit juice on the metabolism of felodipine following intravenous and oral administration.
METHODS: The study had a randomised, four-way, crossover design in 12 healthy males. Single doses of felodipine were given as an intravenous infusion for 1 h (1.5 mg) or as an oral extended release (ER) tablet (10 mg). Grapefruit juice (150 ml) or water was ingested 15 min prior to drug intake.
RESULTS: Intake of grapefruit juice did not significantly alter the intravenous pharmacokinetics of felodipine compared to control treatment, whereas after oral drug administration it did lead to an increase in the mean AUC and Cmax by 72% and 173%, respectively, and the mean absolute bioavailability was increased by 112%. The fraction of the oral felodipine dose reaching the portal system was increased from 45% to 80% when intake of drug was preceded by grapefruit juice ingestion. The pharmacokinetics of the primary metabolite, dehydrofelodipine, was affected by the intake of juice, resulting in a 46% increase in Cmax. Juice intake immediately before oral felodipine resulted in more pronounced haemodynamic effects of the drug as measured by diastolic blood pressure and heart rate. However, the haemodynamic effects of the intravenous administration were not altered by juice intake. Vascular-related adverse events were reported more frequently when oral drug administration was preceded by juice intake compared with control treatment. Taking grapefruit juice immediately prior to intravenous felodipine administration did not cause any alteration in the adverse event pattern.
CONCLUSION: The main acute effect of the grapefruit juice on the plasma concentrations of felodipine is mediated by inhibition of gut wall metabolism.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9174684     DOI: 10.1007/s002280050263

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  30 in total

1.  Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.

Authors:  H Takanaga; A Ohnishi; H Matsuo; H Murakami; H Sata; K Kuroda; A Urae; S Higuchi; Y Sawada
Journal:  Br J Clin Pharmacol       Date:  2000-01       Impact factor: 4.335

Review 2.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 3.  The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?

Authors:  Margaret M Doherty; William N Charman
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Grapefruit juice: potential drug interactions.

Authors:  James Maskalyk
Journal:  CMAJ       Date:  2002-08-06       Impact factor: 8.262

Review 5.  [Effect of intestinal cytochrome P450 3A on phytochemical presystemic metabolism].

Authors:  Fang Xia; Xiao-yin Chen
Journal:  Chin J Integr Med       Date:  2005-09       Impact factor: 1.978

6.  Interactions of grapefruit juice and cardiovascular medications: A potential risk of toxicity.

Authors:  Gareth E Lim; Timao Li; Harpal S Buttar
Journal:  Exp Clin Cardiol       Date:  2003

Review 7.  Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

Authors:  Carl J Fichtenbaum; John G Gerber
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 8.  Grapefruit-medication interactions: forbidden fruit or avoidable consequences?

Authors:  David G Bailey; George Dresser; J Malcolm O Arnold
Journal:  CMAJ       Date:  2012-11-26       Impact factor: 8.262

Review 9.  Grapefruit juice-drug interactions.

Authors:  D G Bailey; J Malcolm; O Arnold; J D Spence
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

10.  Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system.

Authors:  Ram P Kapil; Alessandra Cipriano; Gregory H Michels; Peter Perrino; Sarah A O'Keefe; Manjunath S Shet; Salvatore V Colucci; Robert J Noveck; Stephen C Harris
Journal:  Clin Drug Investig       Date:  2012-09-01       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.